x

Search for a clinical trial

* (*) mandatory field

149 Result(s)

Sort by

Recruiting trial = Recruiting trial
; Ongoing trial = Ongoing trial
; Funded by an IRDiRC member = ; Member of a ERN =

National clinical trial(s)

FRANCE

OCCITANIE
MONTPELLIER

AUSTRIA

OBERÖSTERREICH
LINZ

Ongoing trial
MAINTAIN: Prospective randomized Multicenter study in first-line treatment of Advanced progredIeNT follicular And other IndoleNt and mantle cell lymphomas (phase III) - AT
Kepler Universitätsklinikum - Med Campus III.
Universitätsklinik für Hämatologie und Internistische Onkologie

AUSTRIA

STEIERMARK
GRAZ

Recruiting trial
Ongoing trial
POLE-1: Pembrolizumab in Marginal Zone Lymphoma - a multicenter open label single-arm phase II study - AT
Medizinische Universität Graz
Klinische Abteilung für Hämatologie

AUSTRIA

TIROL
INNSBRUCK

AUSTRIA

WIEN
ADDRESS: NOT PROVIDED - AT

AUSTRIA

WIEN
WIEN

Recruiting trial
Ongoing trial
COUP-1: Copanlisib and Rituximab in Marginal Zone Lymphoma Patients (Phase 2) - AT
Allgemeines Krankenhaus der Stadt Wien
Klinische Abteilung für Onkologie

AUSTRIA

WIEN
WIEN

Recruiting trial
Ongoing trial
POLE-1: Pembrolizumab in Marginal Zone Lymphoma - a multicenter open label single-arm phase II study - AT
Allgemeines Krankenhaus der Stadt Wien
Klinische Abteilung für Onkologie

GERMANY

Baden-Württemberg
ULM

Recruiting trial
Ongoing trial
OLYMP-1: Obinutuzumab in Marginal Zone Lymphoma
Universitätsklinikum Ulm
Institut für Experimentelle Tumorforschung

GERMANY

Baden-Württemberg
ULM

Ongoing trial
COUP-1: Copanlisib and Rituximab in Marginal Zone Lymphoma Patients
Universitätsklinikum Ulm
Institut für Experimentelle Tumorforschung

GERMANY

Baden-Württemberg
ULM

Recruiting trial
Ongoing trial
CITADEL-204: A Study of Parsaclisib in Subjects With Relapsed or Refractory Marginal Zone Lymphoma -DE-
Universitätsklinikum Ulm
Institut für Experimentelle Tumorforschung

GERMANY

Bayern
MÜNCHEN

GERMANY

Schleswig-Holstein
KIEL

Ongoing trial
A Multicenter, Open-Label, Phase 2 Study of the Bruton Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Subjects with Relapsed/Refractory Marginal Zone Lymphoma - DE
Universitätsklinikum Schleswig-Holstein - Campus Kiel
Klinik für Innere Medizin II - Hämatologie und Onkologie

GERMANY

Schleswig-Holstein
KIEL

SPAIN

Andalucía
CÁDIZ

Recruiting trial
Ongoing trial
LYMRIT-37-01: A Phase I/II Study of 177Lu-HH1 (Betalutin®) Radioimmunotherapy for Treatment of Relapsed Non-Hodgkin Lymphoma - ES
Hospital Universitario Puerta del Mar
Unidad clínica de Hematología, Inmunología y Genética

SPAIN

Castilla - León
SALAMANCA

SPAIN

Castilla - León
SALAMANCA

SPAIN

Cataluña
BARCELONA

SPAIN

Cataluña
SABADELL

Recruiting trial
Ongoing trial
LYMRIT-37-01: A Phase I/II Study of 177Lu-HH1 (Betalutin®) Radioimmunotherapy for Treatment of Relapsed Non-Hodgkin Lymphoma - ES
Corporación Sanitaria Parc Taulí. Hospital de Sabadell
Servicio de Hematología y Hemoterapia

SPAIN

Comunidad Valenciana
VALENCIA

SPAIN

Comunidad Valenciana
VALENCIA

SPAIN

Madrid
ADDRESS: NOT PROVIDED - ES

SPAIN

Madrid
MAJADAHONDA

Recruiting trial
Ongoing trial
Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib After Completion of Ibrutinib Clinical Trials (Phase IV) - ES
Hospital Universitario Puerta de Hierro - Majadahonda
Servicio de Hematología y Hemoterapia

SPAIN

Madrid
MAJADAHONDA

Recruiting trial
Ongoing trial
LYMRIT-37-01: A Phase I/II Study of 177Lu-HH1 (Betalutin®) Radioimmunotherapy for Treatment of Relapsed Non-Hodgkin Lymphoma - ES
Hospital Universitario Puerta de Hierro - Majadahonda
Servicio de Oncología Médica

SWITZERLAND

Suisse Italienne
BELLINZONA

Ongoing trial
MALIBU Trial - Phase II Study of Combination Ibrutinib and Rituximab in Untreated Marginal Zone Lymphomas - CH
Istituto di Ricerca in Biomedicina
Istituto oncologico di ricerca (IOR)

SWITZERLAND

Suisse Italienne
BELLINZONA

FRANCE

AUVERGNE-RHONE-ALPES
PIERRE-BENITE

GERMANY

Nordrhein-Westfalen
KÖLN

GERMANY

Nordrhein-Westfalen
MÜNSTER

Recruiting trial
Ongoing trial
A Phase I/II Safety, Dose Finding and Feasibility Trial of MB-CART19.1 in Patients With Relapsed or Refractory CD19 Positive B Cell Malignancies
Universitätsklinikum Münster
Klinik für Kinder- und Jugendmedizin - Pädiatrische Hämatologie und Onkologie

SPAIN

Madrid
MADRID

Recruiting trial
Ongoing trial
A phase I/II, multicenter, open-label study of MAK683 in adult patients with advanced malignancies - ES
Hospital Universitario 12 de Octubre
Unidad de Ensayos Clínicos de Fase Temprana en Hematología

GERMANY

Baden-Württemberg
HEIDELBERG

GERMANY

Bayern
REGENSBURG

Recruiting trial
Ongoing trial
INFORM2 NivEnt: exploratory multinational phase I/II combination study of Nivolumab and Entinostat in children and adolescents with refractory high-risk malignancies
Universitätsklinikum Regensburg
Abteilung für Pädiatrische Hämatologie, Onkologie und Stammzelltransplantation

GERMANY

Nordrhein-Westfalen
ESSEN

Recruiting trial
Ongoing trial
INFORM2 NivEnt: exploratory multinational phase I/II combination study of Nivolumab and Entinostat in children and adolescents with refractory high-risk malignancies
Universitätsklinikum Essen
Klinik für Kinderheilkunde III - Abteilung für pädiatrische Hämatologie und Onkologie

BELGIUM

ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS

Ongoing trial
STEP: Sorafenib Long Term Extension Program - BE
Cliniques universitaires Saint-Luc - UCLouvain
Pneumologie_Oncologie thoracique

Multinational clinical trial(s)

UNITED STATES

Washington
ADDRESS: NOT PROVIDED - US

UNITED STATES

Washington
ADDRESS: NOT PROVIDED - US